Skip to main content
OpenTrials
Completed

NCT Number: NCT01708304

Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)

The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Behavior Brain Diseases Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction Cognitive Impairment Dementia Memory Disorders Memory Impairment Mental Disorders Motor Activity Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Tauopathies

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Washington

Seattle, Washington, 98195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Care Recipients must

  • Have a diagnosis of dementia
  • Be 65 years of age or older
  • Currently exercise no more than 150 minutes a week and not regularly participate in a formal exercise program.

Caregivers must

  • Live in the community
  • Provide care to the care recipient with dementia

Exclusion criteria

Either Care-recipient or Caregiver must not

  • Plan to move to a long-term residential care setting within 6 months of enrollment.
  • Plan to move from the study geographic area within 4 months of enrollment.
  • Have a known terminal illness (with death anticipated within the next 12 months)
  • Have had a hospitalization for a psychiatric disorder in the 12 months prior to baseline
  • Be actively suicidal, hallucinating, or delusional
  • Be blind, deaf, or not ambulatory

Treatment and study plan

RDAD

Behavioral

Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.

Primary outcomes

  1. Minutes of exercise per week

    Time frame: Change from baseline in number of minutes of exercise each week during treatment phase of study, weeks 7-12

    Caregivers will track the number of minutes per week the care recipients engage in exercise recommended by the coach.

  2. Restricted Activity Days

    Time frame: Baseline

    Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.

  3. Restricted Activity Days

    Time frame: Change from Baseline to Pre-Treatment (6 weeks)

    Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.

  4. Restricted Activity Days

    Time frame: Change from Baseline to Post- Treatment 1 (13 weeks)

    Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.

  5. Restricted Activity Days

    Time frame: Change from Baseline to Post-Treatment 2 (30 weeks)

    Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.

  6. Restricted Days of Activity

    Time frame: Change from Baseline to 13 Month Follow-Up

    Restricted Activity Days measures how much the participant cut down his/her usual activities in the previous two weeks because of injury or illness and how many days the participant stayed in bed in the previous two weeks because of injury or illness.

  7. Independence/Residential Status

    Time frame: Change from Baseline to 13 Month Follow-Up

    All participants will be in independent living situations at baseline. Any move from independent living to a care facility will be documented throughout the 13 month study.

Secondary outcomes

  1. Revised Memory and Behavior Problem Checklist (RMBPC)

    Time frame: Baseline

    Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.

  2. Revised Memory and Behavior Problem Checklist (RMBPC)

    Time frame: Change from Baseline to Pre-Treatment (6 weeks)

    Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.

  3. Revised Memory and Behavior Problem Checklist (RMBPC)

    Time frame: Change from Baseline to Post-Treatment 1 (13 weeks)

    Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.

  4. Revised Memory and Behavior Problem Checklist (RMBPC)

    Time frame: Change from Baseline to Post-Treatment 2 (30 weeks)

    Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.

  5. Revised Memory and Behavior Problem Checklist (RMBPC)

    Time frame: Change from Baseline to 13 Month Follow-Up

    Checklist rates 24 care recipient behaviors for frequency of occurrence and caregiver reaction.

  6. Quality of Life-AD

    Time frame: Baseline

    This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.

  7. Quality of Life-AD

    Time frame: Change from Baseline to Pre-Treatment (6 weeks)

    This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.

  8. Quality of Life-AD

    Time frame: Change from Baseline to Post-Treatment 1 (13 weeks)

    This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.

  9. Quality of Life-AD

    Time frame: Change from Baseline to Post-Treatment 2 (30 weeks)

    This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.

  10. Quality of Life-AD

    Time frame: Change from Baseline to 13 Month Follow-Up

    This 13-item measure is specifically designed for individuals with dementia and focuses on quality of life domains identified as important for cognitively impaired older adults.

  11. CES-D

    Time frame: Baseline

    This 20-item scale that assesses depression in caregivers.

  12. CES-D

    Time frame: Change from Baseline to Pre-Treatment (6 weeks)

    A 20-item scale that assesses depression in caregivers.

  13. CES-D

    Time frame: Change from Baseline to Post-Treatment 1 (13 weeks)

    A 20-item scale that assesses depression in caregivers.

  14. CES-D

    Time frame: Change from Baseline to Post-Treatment 2 (30 weeks)

    A 20-item scale that assesses depression in caregivers.

  15. CES-D

    Time frame: Change from Baseline to 13 Month Follow-Up

    A 20-item scale that assesses depression in caregivers.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Registry information

Official study title

From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services

Acronym: RDAD

Important dates

Study start
2012
Primary completion
2017
Study completion
2017
First posted
Oct 16, 2012
Registry last updated
Sep 15, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.